Filament Health Corp.
(FH) (
N.FH,
Forum) – a leading exclusively-natural psychedelic drug development company – today released its Q2 unaudited financial results and business highlights for the period ended June 30, 2021.
Filament announced an active quarter punctuated by industry-leading developments, including the issuance of a patent for the extraction of natural psilocybin and the advancement of its proprietary natural psychedelic extracts through FDA clinical trials.
Developments include a $7.8 million cash position, closing on a $5 million private placement. go-public transaction and financing, FDA clinical trial progress, licensing expansion, and first patent issuance
Fully story
here.
New to investing in Cannabis? Check out Stockhouse tips on How to Invest in Cannabis Stocks and some of our Top Cannabis Stocks.
For more of the latest info on Cannabis, check out the Cannabis Trending News hub on Stockhouse.
FULL DISCLOSURE: Filament Health Corp. is a client of Stockhouse Publishing.